Western Blot: PSMD11 Antibody [NBP1-46191] - Treatment of human skin fibroblasts with 6BIO activated proteostatic modules. Representative immunoblot analyses of the autophagy-related Beclin1 and the 26S proteasome ...read more
Independent Antibodies: Western Blot: PSMD11 Antibody [NBP1-46191] - Whole cell lysate from HeLa (5, 15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded), 293T (T; 50 mcg), and mouse NIH3T3 (M; 50 mcg) cells. ...read more
The immunogen for this product maps to a region between residue 175 and 225 of human Proteasome (Prosome, Macropain) 26S Subunit, non-ATPase, 11 using the numbering given in entry NP_002806.2 (GeneID 5717).
Rat (100%), Xenopus (100%), Zebrafish (100%), Bovine (100%). Backed by our 100% Guarantee.
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
PSMD11 (Proteasome 26S non-ATPase subunit 11), also known as S9, Rpn6 or p44.5, has multi-subunit protease complexes consisting of 20S subunits composed of four seven-numbered rings with two outer rings containing alpha subunits and two central rings composed of beta subunits, and 19S caps of 6 ATPase and 11 non-ATPase subunits. PSMD11 is the main proteolytic enzyme that functions in ATP-dependent degradation of ubiquitinated proteins
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our PSMD11 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.